Patents Assigned to Inserm
  • Method for screening peptides for use in immunotherapy
    Patent number: 7425606
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: September 16, 2008
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave Roussy (IGR)
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, Alexandre David Gross
  • Neuroprotective therapeutics preventing ERK/MAPK activation through the NMDA receptor
    Patent number: 7425614
    Abstract: Methods for identifying neuroprotective compounds, as well as compositions and methods for treating subjects suffering from neurological diseases or disorders are provided.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: September 16, 2008
    Assignees: Children's Medical Center Corporation, Institut National de la Sante et de la Recherche Medical (INSERM)
    Inventors: David Clapham, Grigory Krapivinsky, Igor Medina, Ben-Ari Yehezkel
  • compounds and anti-infection applications thereof
    Patent number: 7422754
    Abstract: The invention provides novel Neisseria meningitides (Nm) polypeptides and polynucleotides which cover the Nm genetic diversity, and which correspond to polypeptide of Nm outer membrane and/or periplasma, and to methods for producing such Nm compounds. Also provided are anti-Nm infection, and particularly diagnostic. prophylactic and therapeutic uses thereof.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: September 9, 2008
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Max-Planck Gesellschaft zur Forderung des Wissenschaften E.V.
    Inventors: Xavier Nassif, Colin Tinsley, Silke Klee, Mark Achtman, Petra Merker
  • Use of Antagonists of the Cbi Receptor For the Manufacture of a Composition Useful For the Treatment of Hepatic Diseases
    Publication number: 20080214449
    Abstract: The invention relates to the use of antagonists to the CB1 receptor for the preparation of a composition for the treatment of hepatic diseases and preferably to the use of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide.
    Type: Application
    Filed: March 8, 2005
    Publication date: September 4, 2008
    Applicants: Inserm, Sandofi-Aventis
    Inventors: Sophie Lotersztajn, Ariane Mallat, Pascale Grenard, Boris Julien, Jeanne V. Nhieu
  • Transgenic Animals and Methods of Making Recombinant Antibodies
    Publication number: 20080196112
    Abstract: The present invention concerns a means for obtaining cells which produce human, humanized or chimeric antibodies in commercially useful quantities. The invention permits high antibody producer cells to be selected and isolated from animals for use in culture to produce antibodies. The invention also provides methods for the affinity maturation of human, humanized or chimeric immunoglobulins.
    Type: Application
    Filed: April 28, 2006
    Publication date: August 14, 2008
    Applicants: Innate Pharma, S.A., INSERM (Institut National De La Sante Et De La Recherche Medicale)
    Inventors: Francois Romagne, Bernard Malissen
  • Anti Tfr Antibody
    Publication number: 20080193453
    Abstract: Abstract The invention relates to the monoclonal antibody A24 directed against the transferrin receptor This antibody is in particular useful as an antiproliferative agent.
    Type: Application
    Filed: April 30, 2004
    Publication date: August 14, 2008
    Applicant: INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Renato Monteiro, Olivier Hermine, Ivan Moura, Yves Lepelletier
  • Methods And Devices For Delivering A Therapeutic Product To The Ocular Sphere Of A Subject
    Publication number: 20080183123
    Abstract: The present invention relates, generally, to improved methods of delivering a biologically active agent, in particular a therapeutic or prophylactic nucleic acid, to the ocular sphere of a subject comprising administering said agent to the ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells. More particularly, the invention relates to devices, their uses, notably in gene therapy, and to methods for treating pathologies of the ocular sphere by specific ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration of a therapeutic product and transfer thereof into the ocular tissue to be treated. This invention also relates to pharmaceutical compositions comprising the product in a form suitable for ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration, their preparation and uses.
    Type: Application
    Filed: April 18, 2006
    Publication date: July 31, 2008
    Applicant: INSERM (Institute National de la Sante et de la Recherche Medicalc)
    Inventors: Francine Behar-Cohen, David Benezra, Pascal Bigey, Carole Bloquel, Daniel Scherman
  • Means for the diagnosis and therapy of CTCL
    Patent number: 7399595
    Abstract: A means for the diagnosis and therapy of T lymphomas, in particular Cutaneous T Cell Lymphomas (“CTCL”) are provided. Tumor markers which are universal for CTCL are described. More particularly, a molecule, termed SC5 by the inventors, an allelic form of p140, and biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL are described.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: July 15, 2008
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Armand Bensussan, Martine Bagot, Laurence Boumsell, Allessandro Moretta
  • Mutated gene coding for a lat protein and the biological applications thereof
    Patent number: 7399901
    Abstract: The present invention relates to a mutated gene coding for a mutant LAT protein leading to exaggerated TH2 differentiation. The invention relates to biological structures containing the mutant, particularly non-human LAT gene, mutated animals, plasmids, chromosomal DNAs, embryos comprising the mutated gene, and applications thereof. The invention further relates to screening methods for drugs useful for treatment against asthma and allergy. Otherwise, the invention relates to methods for producing IgE antibodies.
    Type: Grant
    Filed: February 14, 2003
    Date of Patent: July 15, 2008
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Marie Malissen, Bernard Malissen, Enrique Aguado Vidal
  • NPHS2 gene involved in the steroid-resistant nephrotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
    Patent number: 7388086
    Abstract: The invention concerns a novel gene, called NPHS2 gene coding for a protein involved in the cortico-resistant nephrotic syndrome, and diagnostic and therapeutic uses of the novel identified nucleotide sequences and amino acids.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: June 17, 2008
    Assignee: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Corinne Antignac, Nicolas Boute
  • Nucleic acids and polypeptides specific for pathogenic strains of the genus
    Patent number: 7384768
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 3, 2004
    Date of Patent: June 10, 2008
    Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
  • Polynucleotide and protein involved in synaptogenesis variants thereof and their therapeutic and diagnostic uses
    Patent number: 7384740
    Abstract: The present invention provides a method of diagnosing autism linked to a mutation in the polynucleotide of SEQ ID NO: 12 or the polypeptide of SEQ ID NO: 14, or a propensity therefor, in a human, where the mutation results in altered synapse formation.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: June 10, 2008
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Pasteur, Assistance Publique-Hopitaux de Paris
    Inventors: Thomas Bourgeron, Stephane Jamain, Helene Quach, Catalina Betancur, Marion Leboyer, Christopher Gillberg
  • Methods of treating restenosis
    Publication number: 20080112930
    Abstract: Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.
    Type: Application
    Filed: November 6, 2007
    Publication date: May 15, 2008
    Applicants: The General Hospital Corporation, Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: Roger Hajjar, Anne-Marie Lompr, Larissa Lipskaia, Federica Monte
  • Tri1 Cells for Use in Atherosclerosis
    Publication number: 20080107663
    Abstract: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.
    Type: Application
    Filed: August 11, 2004
    Publication date: May 8, 2008
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), TXCELL
    Inventors: Herve Groux, Alain Tedgui, Ziad Mallat, Valerie Brun
  • DNA and proteins or peptides specific of bacteria of the species, methods for obtaining them and biological applications thereof
    Patent number: 7368556
    Abstract: The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in Neisseria meningitidis, but not in Neisseria gonorrhoeae, or in Neisseria lactamica except the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp C, opc, por A, rotamase the sequence IC1106, IgA protease, pilline, pilC, transferrin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: May 6, 2008
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Xavier Nassif, Colin Tinsley
  • Alternative oxidase and uses thereof
    Publication number: 20080103088
    Abstract: The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in Drosophila has been shown to confer spectacular cyanide-resistance to mitochondrial substrate oxidation, alleviate oxidative stress, apoptosis susceptibility and metabolic acidosis. AOX is well tolerated when expressed ubiquitously in the whole organism. AOX expression is a valuable tool to limit the deleterious consequences of respiratory chain deficiency.
    Type: Application
    Filed: November 1, 2006
    Publication date: May 1, 2008
    Applicants: LICENTIA LTD., INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Pierre Jean Frederic Rustin, Howard T. Jacobs, Emmanuel Philippe Dassa, Gerrit A. J. Hakkaart, Daniel Jose Moreno Fernandez-Ayala
  • BIPOTENTIAL LIVER CELL LINES FROM WILD-TYPE MAMMALIAN LIVER TISSUE
    Publication number: 20080102057
    Abstract: The present invention relates to a hepatic cell line derived from wild-type mammalian liver tissue by culture methodology, the cells of the cell line being capable of differentiating into hepatocytes and bile duct cells. The present invention also relates to methods of producing such cells as well as to their applications in therapy and as an investigational tool.
    Type: Application
    Filed: January 4, 2008
    Publication date: May 1, 2008
    Applicants: INSERM, Centre National De La Recherche Scient., INSTITUT PASTEUR
    Inventors: Helene Strick-Marchand, Mary Weiss, Serban Morosan, Dina Kremsdorf, Pierre Charneau
  • Use of the gene in the field of angiogenesis
    Patent number: 7364844
    Abstract: The invention concerns a method for diagnosing cavernous angiomas for detecting mutations in the Krit1 gene. More particularly, said detection is performed by using nucleotide sequences. The invention further concerns the use of the Krit1 gene for therapeutic purposes in the field of angiogenesis.
    Type: Grant
    Filed: July 3, 2000
    Date of Patent: April 29, 2008
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Elisabeth Tournier-Lasserve, Sophie Laberge-Le-Couteulx, Pierre Labauge
  • Vegf-C or Vegf-D Materials and Methods for Stimulation of Neural Stem cells
    Publication number: 20080057028
    Abstract: The present invention relates to VEGF-C or VEGF-D materials and methods for promoting growth and differentiation of neural stem cells, neuronal and neuronal precursor cells, oligodendrocytes and oligodendrocyte precursor cells and materials and methods for administering said cells to inhibit neuropathology.
    Type: Application
    Filed: September 23, 2004
    Publication date: March 6, 2008
    Applicants: INSTITUTE NATIONALE DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Kari Alitalo, Marika Karkkainen, Paula Haiko, Kirsi Sainio, Kirmo Wartiovaara, Jean L. Thomas, Anne Eichmann
  • Anti-Cd28 Antibody
    Publication number: 20080038273
    Abstract: The invention concerns an antibody directed against the CD28 receptor and capable of blocking CD28/B7 interaction, and proteins derived from said antibody, for use in particular to block CD28-dependent activation of lymphocytes.
    Type: Application
    Filed: December 26, 2001
    Publication date: February 14, 2008
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Jean-Paul Soulillou, Genevieve Laflamme, Bernard Vanhove, Daniel Olive